Aragen inks deal with Innovent; Lonza and Teva think twice about biologics JV;

> Aragen Bioscience, a Bay Area CRO, has signed on with Innovent Biologics to provide the drugmaker with manufacturing cell lines for biotherapeutic product development. Release

> CRO Novum Pharmaceutical Research Services is opening a 55,000-square-foot, 225-bed facility in Houston to handle Phase I-IV clinical trials. More

> CMO Lonza and drugmaker Teva ($TEVA) are re-evaluating their joint venture to develop, manufacture and sell biosimilars, fretting over regulatory uncertainty. Story

> Parexel International's ($PRXL) Perceptive Informatics unit is launching a new version of its Impact clinical trial management software, touting improved data entry and site monitoring features. News

> Clinilabs is launching a subject-authentication initiative at its Phase I sites, using the Verified Clinical Trials database to prevent dual patient enrollment. Report

> SynteractHCR has appointed a new CIO, CMO and vice president of regulatory affairs. More